RVMD Stock Recent News

RVMD LATEST HEADLINES

RVMD Stock News Image - seekingalpha.com

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President of R&D Wei Lin - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Chris Shibutani - Goldman Sachs Eliana Merle - UBS Alec Stranahan - Bank of America Kelly Shi - Jefferies Jay Olson - Oppenheimer Laura Prendergast - Raymond James Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Q2 2024 Earnings Conference Call.

seekingalpha.com 2024 Aug 11
RVMD Stock News Image - globenewswire.com

REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress.

globenewswire.com 2024 Aug 07
RVMD Stock News Image - globenewswire.com

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

globenewswire.com 2024 Jul 31
RVMD Stock News Image - benzinga.com

As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

benzinga.com 2024 Jul 16
RVMD Stock News Image - globenewswire.com

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC)

globenewswire.com 2024 Jul 11
RVMD Stock News Image - zacks.com

Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com 2024 Jul 10
RVMD Stock News Image - globenewswire.com

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School, and director of the Gastrointestinal Cancer Center and Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.

globenewswire.com 2024 Jul 08
RVMD Stock News Image - prnewswire.com

NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation seeks to determine whether Revolution Medicines's directors breached their fiduciary duties in connection with recent corporate actions.

prnewswire.com 2024 Jul 08
RVMD Stock News Image - globenewswire.com

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference.

globenewswire.com 2024 Jun 05
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire 2024 May 01
10 of 47